• CARI - Caring for Australasians with Renal Impairment. Donor sepsis. Westmead NSW (Australia): CARI - Caring for Australasians with Renal Impairment; 2005 Jul. 9 p. [20 references]



• Caring for Australasians with Renal Impairment. Donor sepsis. Nephrology 2005;10(Suppl 4):S129-32.

This is the current release of the guideline.

Definitions for the levels of evidence (I–IV) can be found at the end of the "Major Recommendations" field.

Guidelines

There is no contraindication to general allocation of cytomegalovirus (CMV) (+) organs; however, the donor should be made aware to enable CMV prophylaxis, particularly for CMV (–) recipients. (Level II evidence)

Suggestions for Clinical Care

(Suggestions are based on Level III and IV evidence)

• Uncontrolled donor sepsis should be a contraindication to kidney donation.
• Donor sepsis, once controlled with appropriate antibiotic therapy, is not a contraindication to kidney donation (Level III evidence).
• Transmission of virus/es from donor to recipient is possible and the risk of this should be minimised by donor assessment and allocation as follows:

  Human immunodeficiency virus (HIV): exclusion if antibody (+) or high-risk behaviour (intravenous [IV] drug abuse, commercial or male-male sex during previous 6 months).

  Hepatitis B: (HB) surface antigen Ag (+) and isolated hepatitis B virus (HBV) core antibody (Ab)+ unsuitable for general donation, consider for HB surface Ag+ recipients. HBV core Ab+ with HBV surface Ab+ (previous infection) allocate to any HBV surface Ab+ (immune) recipient with specific consent.

  Hepatitis C: anti-hepatitis C virus (HCV) (+) – allocate only to anti-HCV (+), RNA (+) recipient with specific consent.

  Epstein Barr Virus: EBV (+) – no contraindication to general allocation, however, recipient requires notification as EBV (-) recipients may incur increased risk of primary infection and post-transplant lymphoproliferative disease.

  Human T-lymphotropic virus (HTLV) I & II and Creutzfeldt-Jakob disease (CJD) occur at extremely low frequencies in Australia and New Zealand, and were not screened for.

  Herpes simplex virus (HSV), herpes zoster virus (HZV), human herpesvirus 6 (HHV-6), and human herpesvirus 8 (HHV-8) are prevalent and may be transmitted, but are not screened for.

• Transmission of syphilis, malaria, rabies and other parasites are unlikely due to rarity of these infections in Australia. However, if donor infection is suspected, appropriate testing and treatment should be given to both donor and recipient.
• A donor will be excluded in the presence of uncontrolled sepsis. If sepsis has occurred but has been controlled with antibiotics, donation should proceed provided the recipient is treated with appropriate antibiotics for at least 3 days post-transplant, and that specific informed consent is obtained from the recipient.
• HIV (+) donors, or those deemed to be at high risk (IV drug abuse, prostitution, male-male sex within the past 6 months) should be excluded from donation.
• Hepatitis B: HB surface Ag+ or isolated HBV core Ab+ unsuitable for donation; HBV core Ab+ and HBV surface Ab+ allocate to any HBV surface Ab+ recipient with specific consent. HBV immunisation should be given to seronegative patients with end-stage kidney disease (ESKD) prior to transplant.
• Hepatitis C: anti-HCV (+) – allocate only to anti-HCV (+), RNA (+) recipient with specific consent.
• Cytomegalovirus: CMV (+) – no contraindication to general allocation, however, donor should be made aware to enable CMV prophylaxis, particularly for CMV (-) recipients (Level II evidence).
• Epstein Barr Virus: EBV (+) – no contraindication to general allocation, however, recipient requires notification as EBV (-) recipients may incur an increased risk of primary infection and post-transplant lymphoproliferative disease.
• HTLV I & II and CJD occur at extremely low frequencies in Australia and New Zealand, and are not screened for. Donors from areas where HTLV is endemic (e.g., Caribbean basin) should be screened.
• HSV, HZV, HHV6 and HHV8 are prevalent and may be transmitted, but are not screened for. Varicella immunisation should be considered for seronegative patients with ESKD prior to transplant, but not post-transplant.
• Syphilis: Transmission of syphilis is possible, however, donation may proceed in the presence of a positive serological test for syphilis (e.g., rapid plasma reagin [RPR]) provided a two-week course of penicillin is given to the recipient and specific consent is obtained.
• Tuberculosis: Active mycobacterial infection is a contraindication to transplantation. Donor chest x-ray is recommended to enable risk assessment and in the deceased donor, any suspicious lesions should undergo biopsy and microscopy. In the live donor situation, chest x-ray is also recommended and any suspicious lesions should be assessed by a respiratory specialist.

Definitions:

Levels of Evidence

Level I: Evidence obtained from a systematic review of all relevant randomized controlled trials (RCTs)

Level II: Evidence obtained from at least one properly designed RCT

Level III: Evidence obtained from well-designed pseudo-randomized controlled trials (alternate allocation or some other method); comparative studies with concurrent controls and allocation not randomized, cohort studies, case-control studies, interrupted time series with a control group; comparative studies with historical control, two or more single arm studies, interrupted time series without a parallel control group

Level IV: Evidence obtained from case series, either post-test or pretest/post-test

None provided

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

• CARI - Caring for Australasians with Renal Impairment. Donor sepsis. Westmead NSW (Australia): CARI - Caring for Australasians with Renal Impairment; 2005 Jul. 9 p. [20 references]



• Caring for Australasians with Renal Impairment. Donor sepsis. Nephrology 2005;10(Suppl 4):S129-32.

Not applicable: The guideline was not adapted from another source.

2005 Jul

Caring for Australasians with Renal Impairment - Disease Specific Society

Industry-sponsored funding administered through Kidney Health Australia

Not stated

Not stated

All guideline writers are required to fill out a declaration of conflict of interest.

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI Institute on March 28, 2008. The information was verified by the guideline developer on June 11, 2008.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.